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Aldehyde dehydrogenases (ALDH) are a family of enzymes primarily involved in the
oxidation of various aldehydes. Most ALDH enzymes derived from mammalian sources have
been shown to exist as homotetramers, consisting of four identical subunits of approximately
54 kDa. The presence of the homotetramer appears to be necessary for enzyme activity. In this
study, recombinant rat liver mitochondrial ALDH (rmALDH) was inhibited in vitro with four
different inhibitors, namely, disulfiram (MW, 296.5), prunetin (MW, 284.3), benomyl (MW,
290.3), and N-tosyl-L-phenylalanine chloromethyl ketone (TPCK) (MW, 351.8). Subsequently,
inhibited rmALDH was analyzed by a novel approach of on-line size exclusion chromatog-
raphy-microelectrospray ionization-mass spectrometry (SEC-mESI-MS) to examine the nonco-
valent quaternary structural stability of the inhibited enzyme. Analysis of native rmALDH by
SEC-mESI-MS revealed predominantly the homotetramer (Mr 5 ;217,457 Da, 60.01%) with
some in-source, skimmer-induced dissociation to afford monomer (Mr 5 ;54,360 Da,
60.01%). Both disulfiram and prunetin inhibited rmALDH by .70% and .90%, respectively,
but did not disrupt the quaternary structure of rmALDH. Furthermore, there was no
detectable change within experimental error (60.01%) of the disulfiram or the prunetin
homotetramers (Mr 5 ;217,448 Da and Mr 5 ;217,446 Da). This may possibly indicate that
inhibition occurred via formation of intramolecular disulfide bond at the enzyme active site,
or weak affinity noncovalent binding. In contrast, benomyl-inhibited rmALDH homotetramer
(.90% inhibition) exhibited a Mr 5 ;217,650 Da (60.01%) corresponding to two butylcar-
bamoyl adducts on two of the four enzyme subunits. The skimmer-induced monomer afforded
a mixture of unmodified rmALDH (Mr 5 ;54,365 Da, 60.01%) and butylcarbamoylated
enzyme (Mr 5 ;54,459 Da, 60.01%). Finally, TPCK (.90% inhibition) modified all four
subunits of rmALDH to give Mr 5 ;218,646 Da (60.01%). In all four cases while significant
enzyme inhibition occurred, no destabilization of the quaternary complex was detected.
(J Am Soc Mass Spectrom 2001, 12, 97–104) © 2001 American Society for Mass Spectrometry
Aldehyde dehydrogenase (ALDH) belongs to afamily of enzymes involved in the oxidation ofin vivo derived aldehydes. One of the major
functions of ALDH is to oxidize acetaldehyde to acetic
acid as part of the metabolic excretion of ethanol from
the body [1–3]. In mammals several ALDH isozymes
exist, which are grouped into three distinct classes
(class I, II, and III) depending on their structure, cata-
lytic characteristics, and subcellular localization [4].
Mitochondrial ALDH (mALDH) belongs to the class II
subgroup and is believed to be primarily responsible
for acetaldehyde metabolism [5, 6]. It is also interesting
to note that most of the ALDH enzymes are reported to
exist as homotetramers, whose presence are necessary
for enzyme activity. They consist of isozyme-specific
subunit monomers of approximately 54 kDa [7, 8].
A number of ALDH inhibitors have been also de-
scribed. The action of disulfiram is probably the most
well characterized, and it has been utilized clinically in
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the aversion therapy of recovering alcoholics. The drug
and/or its metabolites have been proposed to irrevers-
ibly inhibit ALDH by covalently modifying an active
site cysteine residue [9–12]. Other inhibitors of ALDH,
such as prunetin, benomyl, and N-tosyl-L-phenylala-
nine chloromethyl ketone (TPCK), have been reported
to function by a variety of other mechanisms [13–15].
Specifically, it has been suggested that prunetin com-
petitively inhibits cytosolic ALDH and mALDH by
binding to an allosteric site [13]. Benomyl has been
proposed to inactivate the enzyme via the formation of
a butylcarbamoyl conjugate on the enzyme [14]. More-
over, TPCK has been suggested to inhibit ALDH by
covalently modifying Glu-398 located in the active site
pocket, which had not previously been shown to serve
an important role in enzyme function [15]. Although the
kinetic properties of these inhibitors have been charac-
terized, it still remains unclear whether inhibition of
ALDH is caused by direct interaction of the monomer
with the drug/chemical or as a result of destabilizing
protein quaternary structure. This latter event may be
brought about by an inhibitor-induced conformational
change of the monomer resulting in reduced accessibil-
ity of the protein binding domain.
The formation of quaternary protein complexes is an
important process in protein function. Microelectro-
spray mass spectrometry (mESI-MS) has been devel-
oped in recent years, and under certain conditions can
preserve the quaternary structure of proteins in the gas
phase [16–18]. Recently, mESI-MS has found increasing
use in the analysis of noncovalent protein–protein and
protein–drug interactions [16, 17, 19–26]. Specifically,
using mESI-MS, Robinson has reported noncovalent
complex formation in transthyretin [16], Vis et al. de-
tected heterodimers of the type II DNA-binding pro-
teins from bacteria [20], and Bruce et al. showed chap-
erone–ligand noncovalent complex formation [24].
In the present study, we utilize a novel approach of
linking size exclusion chromatography on-line with
mESI-MS (SEC-mESI-MS). Although it has been shown
that on-line size exclusion chromatography-mass spec-
trometry could be used to determine noncovalent me-
tallodrug interactions [27], no studies have been per-
formed, to our knowledge, that show that SEC-mESI-MS
can be used in the characterization of the quaternary
structure of proteins. We demonstrate in this report
characterization of the noncovalent quaternary interac-
tion between subunits of the mALDH tetramer com-
plex, as well as the influence of inhibitors on these
interactions using SEC-mESI-MS. We show direct evi-
dence that native recombinant rat mALDH (rmALDH)
exists as a homotetramer in solution, and that the
inhibition of rmALDH in vitro by disulfiram, prunetin,
benomyl, and TPCK does not significantly interfere
with the quaternary structure of the tetrameric
rmALDH complex, but in some cases structurally mod-
ifies the monomeric subunit.
Experimental
Chemicals
Disulfiram was recrystallized twice in ethanol before
use. NAD1 (grade 1 free acid, 100%) and dithiothreitol
(DTT) were purchased from Boehringer Mannheim
(Mannheim, Germany). Acetaldehyde, epoxy-activated
Sepharose 6B, prunetin, and TPCK were obtained from
Sigma Chemical (St. Louis, MO). Benomyl was pur-
chased from Fluka Chemical (Milwaukee, WI). The
rmALDH cDNA in pT7-7 was a gift from Dr. Henry
Weiner (Purdue University, West Lafayette, IN).
Expression of rmALDH
Recombinant rat liver ALDH was purified by the
method of Jeng and Weiner [28] with some modifica-
tions. Specifically, cells carrying the plasmid that con-
tains the rmALDH cDNA were grown in 2 L of Terrific
Broth supplemented with 100 mg/mL of ampicillin.
After harvesting and lysing the cells, the lysate was
purified using a p-hydroxyacetophonone (pHAP) affin-
ity column. The rmALDH was eluted with 10 mM
pHAP in column equilibration buffer [20 mM sodium
phosphate, 1 mM ethylenediaminetetraacetic acid
(EDTA), 0.1 mM DTT, 50 mM NaCl, pH 7.4]. Eluant
fractions with protein concentration of .0.5 mg/mL
were pooled, and dialyzed twice against a 1-L equili-
bration buffer over 24 h each.
Activity and Inhibition of rmALDH
The enzyme activity assay was performed as previously
described [29]. Briefly, 10 mL of purified rmALDH (2.1
mg/mL) was dispensed into microtiter plate wells in
triplicate followed by addition of 190 mL of sodium
pyrophosphate buffer, pH 8.8, and 25 mL of acetalde-
hyde and NAD1. The final acetaldehyde concentration
was 160 mM, and that of NAD1 was 500 mM. Enzyme
activity was determined by spectrophotometrically
monitoring formation of NADH at 340 nm.
In order to determine IC50 values, 40 mL of stock
rmALDH (0.7 mg/mL) was inhibited with varying
concentrations of disulfiram, prunetin, benomyl, and
TPCK. Note that disulfiram, benomyl, and TPCK were
each dissolved in methanol, while prunetin was dis-
solved in DMSO. One mL of each inhibitor solution at
various concentrations was added to the rmALDH
solution and then incubated at pH 7.4 for 15 min at
room temperature and the enzyme activity was mea-
sured as described above.
On-line SEC-mESI-MS
For SEC-mESI-MS analysis, 40 mL (2.1 mg/mL)
rmALDH in 20 mM sodium phosphate, 1 mM EDTA,
and 50 mM NaCl at pH 7.4 was incubated with 150 mM
disulfiram (3 mL), 500 mM prunetin (1 mL), 500 mM
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benomyl (1 mL), and 100 mM TPCK (4 mL). The solu-
tions were incubated at room temperature for 15 min,
and rmALDH activity was determined. Subsequently
each solution was subjected to SEC-mESI-MS analysis.
Furthermore, rmALDH homotetramers (both native
and inhibited by disulfiram, prunetin, benomyl, and
TPCK) were also collected at the splitter, post-SEC
separation, and subjected to enzyme activity assay. All
of these data are summarized in Table 1.
The size exclusion column used was a Precision
Column PC 3.2 mm i.d. 3 300 mm (2.4 mL) prepacked
with Superdex 200 with a pore size of 100–120 Å
purchased from Amersham-Pharmacia (Piscataway,
NJ). Samples were loaded onto the SEC column with an
injection valve with a 10 mL sample loop. Approxi-
mately 20 mL of sample was loaded to fill the sample
loop, and the injection valve was switched so that the
sample loop was in-line with the SEC column. SEC
separation was subsequently achieved by a constant
flow of 5 mM ammonium acetate in water at 30 mL/min
maintained by using Shimadzu LC-10AD pumps (Shi-
madzu, Columbia, MD). The flow out of the SEC was
split with approximately 300 nL/min flow directed into
the ESI source. Recombinant rat liver mALDH was
analyzed by liquid chromatography-mass spectrometry
using a Finnigan MAT 900 mass spectrometer (Finnigan
MAT GmbH, Bremen, Germany) with a Finnigan MAT
designed electrospray interface. A modified electro-
spray flange was used which sprays from a fused silica
emitter of 20 mm i.d. [30], and the spray chamber was
bathed with SF6 at 1.6 L/min. The spray voltage was
kept at 3.60 kV, and the capillary temperature was
180 °C. The voltages for the capillary and tube lens were
75 and 180 V, respectively. The magnet was scanned
from m/z of 1800 to 8000 at 15 s/decade, and ions
generated were detected by a PATRIC (Position and
Time Resolved Ion Counter) scanning array detector
using an 8% mass window at a voltage of 850 V. The
multiply charged protein spectra were transformed
from the mass-to-charge (m/z) axis to the relative mo-
lecular mass (Mr) axis using deconvolution software
supplied by Finnigan MAT (Bremen, Germany). This
deconvolution algorithm mathematically transforms an
envelope of multiply charged peaks into one peak
corresponding to the Mr value of the protein. This
approach preserves peak shape information from the
original multiply charged spectrum, and provides a
more consistent result than averaging the calculated Mr
from each charge state, because the Finnigan MAT
software labels the most abundant m/z of peaks rather
than their weighted centroid. Transformed Mr values
were found to be within the experimental error of 0.01%
when compared to the Mr values obtained from the
mean of the Mr value calculated from each charge state.
A more detailed discussion of this approach has been
described previously [31]. Finally all analyses were
performed in triplicate and the variation of the multiply
charged spectral data was 60.2 u.
Results and Discussion
In the past, noncovalent multisubunit complex forma-
tion in proteins has been determined mainly by nonde-
naturing gels or differential centrifugation. Although
these methods can provide limited information on
multimer formation, they are rather cumbersome tech-
niques and they do not normally provide a means for
determining accurate molecular weight values. Linking
SEC on-line with mESI-MS affords several apparent
advantages over current methods. One is to provide a
mechanism of separating the tetramers from the mono-
mers or dimers resulted from drug-induced dissocia-
tion if it is to occur. Second, SEC adds a component of
sample desalting and buffer exchange during the sepa-
ration process to increase the sample compatibility to
mass spectrometric analysis. This approach is not only
able to rapidly determine if the noncovalent quaternary
complex has been disrupted, but also provide relatively
accurate measurement of its molecular weight, as well
as allow on-line coupling of the chromatographic step
to the mass spectrometer.
Inhibition Study of rmALDH
Recombinant rat liver mALDH was inhibited with
varying concentrations of disulfiram, prunetin, beno-
myl, and TPCK at pH 7.4 for 15 min at room tempera-
ture. The extent of inhibition was determined from
rmALDH activity assay. The IC50’s of TPCK and beno-
myl were found to be 8.59 and 8.38 mM, respectively.
These values indicated that these agents are potent
inhibitors of rmALDH in vitro, whereas disulfiram and
prunetin were not as potent with IC50 values of 36.4 and
26.7 mM, respectively. This is all summarized in Table 1.
The enzyme was also inhibited individually with dis-
crete concentrations of disulfiram, prunetin, benomyl,
Table 1. Structures of rmALDH inhibitors, along with their
molecular weight, IC50 values, % inhibition post-SEC separation,
as well as change in molecular weight of rmALDH
homotetramer and monomer after incubation with inhibitor
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and TPCK under identical conditions, prior to SEC-
mESI-MS analysis. The rmALDH exhibited .70% inhi-
bition by disulfiram, and the other three inhibitors all
inhibited rmALDH by .90%.
SEC-mESI-MS of Native mALDH
When native rmALDH was subjected to SEC-mESI-MS
analysis, the enzyme eluted from the SEC column as a
single entity, as shown in Figure 1. The ion response
was detected at an elution time of ;44 min. We
observed that native rmALDH was present in solution,
primarily as the homotetramer. A series of multiply
charged ions were detected at m/z ;6300–7500 in the
SEC-mESI-MS spectrum (Figure 2A). These ions on
transformation afforded a Mr of ;217,457 Da (Figure
2B). This is consistent with the rmALDH homotetramer,
which has a calculated Mr of 217,472 Da, and the mass
difference is within the experimental error of 60.01%.
It has been shown that with low electrospray voltage
values the noncovalent quaternary structures of pro-
teins, such as the tetramer complex in transthyretin,
could be completely preserved [16]. However, by in-
creasing the skimmer voltage to a slightly higher value,
partial dissociation of the complex could be induced
due to increased energy of collision in the electrospray
source. Therefore, under the ionization conditions we
adopted, we were also able to observe the multiply
charged ions of the native rmALDH monomers (m/z
;2200–3500) due to skimmer-induced dissociation in
the mESI source. The Mr of the monomer was deter-
mined to be 54,360 Da (Figure 2C), which was also in
good agreement with the theoretical molecular weight
of 54,368 Da as calculated from rmALDH protein se-
quence published in SWISS-PROT. We also observed a
minor component at 54,272 Da, which is likely to be the
truncated enzyme with the loss a serine at either the N
or C terminus.
Figure 1. SEC-mESI-MS ion chromatogram of native rmALDH.
Native rmALDH eluted from the SEC column as a single entity at
an elution time of ;44 min. No evidence was detected for the
presence (based on elution time) of the rmALDH monomer. The
slight ion instability (marked asterisk) is caused by a change in
viscosity as the protein plug moves through the splitter.
Figure 2. Positive ion SEC-mESI-MS analysis of native rmALDH.
(A) mESI-MS analysis of native rmALDH. Multiply charged ions
of the homotetramer (m/z ;6300–7500) and the skimmer-induced
monomer (m/z ;2200–3500) are both detected. (B) Transformed
spectrum of native rmALDH tetramer, with a Mr of 217,457 Da.
(C) Transformed spectrum of skimmer-induced rmALDH mono-
mer with a Mr of 54,360 Da as well as ragged terminus rmALDH
at 54,272 Da.
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Disulfiram-Inhibited rmALDH
Disulfiram is probably the best known irreversible
inhibitor of ALDH, and has been the only drug ap-
proved by the FDA to be used in the aversion therapy of
recovering alcoholics. Disulfiram has been demon-
strated to inhibit rmALDH both in vitro and in vivo [32,
33]. We report here that disulfiram inhibited the recom-
binant rmALDH by ;70% after a 15-min incubation.
When the inhibited enzyme was analyzed by SEC-mESI-
MS, we found that it also eluted as one peak from the
SEC column as observed in Figure 1 for the native
enzyme. Its mass spectrum showed that the enzyme
was still present as a homotetramer (m/z ;5600–7500)
(Figure 3A). In addition, no apparent molecular weight
change was detected on the homotetramer (Mr 5
;217,448 Da) (Figure 3B) as compared to that of the
native enzyme (Mr 5 ;217,457 Da) (Figure 2B) within
the instrument error window of 60.01%. This result
was consistent with previous findings in that disulfiram
inhibits mALDH in vitro by inducing the formation of
an intramolecular disulfide bond possibly via a very
rapid initial unstable intermolecular mixed disulfide
exchange [9–11]. In addition, no skimmer-induced
monomer was observed in the multiply charged spec-
trum of disulfiram-inhibited rmALDH (Figure 3A) us-
ing identical mESI source conditions as for native
rmALDH. However, by increasing the skimmer volt-
age, it was possible to induce some dissociation (;35%)
of the rmALDH homotetramer. Addition of methanol
(;40% by total volume) to the disulfiram-inhibited
rmALDH should have completely dissociated the ho-
motetramer by denaturing the monomeric units. How-
ever, ;20% of rmALDH homotetramer was still de-
tected (data not shown), indicating that disulfiram
caused some interdisulfide cross linkage between
rmALDH monomers.
Prunetin-Inhibited mALDH
Prunetin has previously been shown to be a competitive
inhibitor of ALDH [13]. It was reported to be competi-
tive against both NAD1 and propionaldehyde, yet it
does not interact with either the substrate or NAD1
binding site [13]. Incubation of rmALDH with prunetin
afforded 90% inhibition of the enzyme activity. The
prunetin-inhibited rmALDH also eluted as one entity
on the SEC column, and the multiply charged ions of
the homotetramer complex (Figure 4A) could be de-
tected at m/z ;6300–7500. Weiner [13] has shown that 1
mol of prunetin binds to each mole of functional
homotetrameric rmALDH at an allosteric site, and
thereby influences the substrate and cofactor binding.
However, the SEC-mESI-MS analysis showed that there
were no apparent mass changes in either the homotet-
ramer (Mr 5 217,446 Da) or the monomer (Mr 5
54,354 Da) of the prunetin-inhibited enzyme (Figure
4B, C, respectively). All this data indicate that prunetin
does not form a covalent adduct with rmALDH. How-
ever, the enzyme was still inhibited after collection at
the splitter, post-SEC separation (Table 1). This may be
explained either by formation of a disulfide link
brought about by redox chemistry, or more likely that
the prunetin–rmALDH noncovalent interaction is dis-
rupted in the mESI-source region. This is under further
investigation.
Benomyl-Inhibited rmALDH
Benomyl has been shown to be a potent inhibitor of
ALDH both in vitro and in vivo [14]. The mechanism by
which benomyl inhibits ALDH was proposed to be
analogous to that determined for the carbamate pesti-
cides, specifically via the adduction of its butylcar-
bamoyl moiety to the enzyme [14]. When benomyl was
incubated with rmALDH for 15 min, we found that it
also inhibited the enzyme by 90%. Benomyl-inhibited
enzyme also was found to be present as a homotetramer
(m/z ;6400–7600) (Figure 5A), and the Mr was deter-
mined to be ;217,650 Da (Figure 5B). This Mr value
Figure 3. Positive ion SEC-mESI-MS analysis of disulfiram-inhib-
ited rmALDH. (A) mESI-MS analysis of disulfiram-inhibited
rmALDH. Multiply charged ions of the homotetramer (m/z
;5600–7500) could be detected, but the skimmer-induced mono-
mer was not detectable. (B) Transformed spectrum of disulfiram-
inhibited rmALDH. The Mr of the homotetramer was determined
to be 217,448 Da.
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reflected a mass increase of ;210 Da as compared to
that of the native homotetramer of rmALDH, and could
be accounted for by the adduction of two butylcar-
bamoyl groups (199 Da for each group). The skimmer-
induced monomer was also readily detectable with
multiply charged ions observed at m/z ;2200–3300
Figure 4. Positive ion SEC-mESI-MS analysis of prunetin-inhib-
ited rmALDH. (A) mESI-MS analysis of prunetin-inhibited
rmALDH. Multiply charged ions of both the homotetramer (m/z
;6300–7500) and the monomer (m/z ;2200–3500) were detected.
(B) Transformed spectrum of the homotetramer of prunetin-
inhibited rmALDH with a Mr of 217,446 Da. (C) Transformed
spectrum of skimmer-induced monomer of prunetin-inhibited
rmALDH. The Mr of the enzyme was found to be 54,354 Da with
the truncated enzyme also detected at 54,274 Da.
Figure 5. Positive ion SEC-mESI-MS analysis of benomyl-inhib-
ited rmALDH. (A) mESI-MS analysis of benomyl-inhibited
rmALDH. Multiply charged ions of both the homotetramer (m/z
;6300–7500) and the skimmer-induced monomer (m/z ;2200–
3300) were detected. (B) Transformed spectrum of benomyl-
inhibited mALDH. The Mr of the homotetramer was 217,650 Da,
which was ;200 Da higher than that of the native homotetramer.
(C) Transformed spectrum of benomyl-inhibited mALDH. The
main figure has a smoothing factor of 5. However, in the inset, a
smoothing factor of only 3 has been applied. The ions at Mr 5
54,365 and 54,276 Da correspond to the native monomer of
rmALDH and its ragged terminus homolog. The ions at Mr 5
54,459 and 54,380 Da correspond to the butylcarbamoylated
enzymes.
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(Figure 5A). However, on close inspection of the trans-
formed spectrum, four distinct Mr ions are clearly
discernible, as seen in Figure 5C (inset). The ion at Mr 5
54,365 (60.01%) is unadducted monomeric rmALDH,
whereas the ion at Mr 5 54,459 (60.01%) is adducted
rmALDH modified with a single butylcarbamoyl
group. The ion at Mr 5 54,276 is the unmodified ragged
N- or C-terminus rmALDH, and the Mr 5 54,380 is its
single, butylcarbamoyl adducted counterpart.
The presence of significant amounts of unadducted
rmALDH as well as adducted enzyme is consistent with
the indication from the mass increase observed in the
homotetramer (Figure 5B) that only two of the four
subunits of mALDH were modified by benomyl. The
results presented here are in good agreement with
previous reports that there are interactions between the
four subunits of mALDH, and the enzyme does not
function as four distinct units [35, 36]. Instead, mALDH
has been characterized to function with half-site reac-
tivity [35].
TPCK-Inhibited rmALDH
It has been reported that a variety of serine protease
inhibitors are capable of inhibiting ALDH. TPCK is a
specific serine protease inhibitor, and is still used to
inactivate chymotrypsin in preparations of trypsin [15],
and it also fulfills the criteria for an active-site-directed
inhibitor of ALDH [37]. In this study, rmALDH was
inhibited .90% when incubated with TPCK. Subse-
quently, the TPCK-inhibited rmALDH was analyzed by
SEC-mESI-MS, and a series of multiply charged ions
(m/z ;6300–7700) corresponding to the TPCK-inhibited
rmALDH homotetramer were detected (Figure 6A). The
Mr of the inhibited enzyme was 218,646 Da (Figure 6B),
which is ;1200 Da higher than that of the native
homotetramer (Figure 2B). The skimmer-induced
monomer afforded a series of multiply charged ions at
m/z ;2000–3500, which on transformation revealed a
predominant ion at Mr 5 54,673 Da (Figure 6B). This
reflects a mass increase of ;315 Da indicating that
covalent modification of rmALDH occurs via SN1 or
SN2 nucleophilic attach at the methylene carbon of
TPCK, with ultimate displacement of Cl. The relatively
minor component of the ragged N- or C-terminus
monomer observed previously in the native rmALDH
also showed a 300 Da increase in molecular mass. The
correlation between the molecular weight increases in
the monomer and the homotetramer was an indication
that each monomer in the homotetramer complex was
adducted by one TPCK molecule. In addition, the
multiply charged ions of the monomer also showed a
homogeneous pattern, which lent further support to the
finding that covalent modification was uniform on all
four subunits of the inhibited enzyme. It has been
shown that TPCK inhibits mALDH by reacting with
E-398, and the saturation kinetics suggested that the
interaction involves a covalent bond formation [15],
which was consistent with our findings. However,
Dryjanski et al. demonstrated that only 2 mol of TPCK
were needed to fully inactivate the cytosolic isoform of
ALDH. The difference in the TPCK binding stoichiom-
etry in this work could simply be due to the fact that
although only 2 mol of TPCK are needed to inactivate
the enzyme, further adduct formation occurred due to
the amount of TPCK added to the protein solution.
In conclusion, we have shown in this report that
rmALDH exists as homotetramers in solution, and the
tetramer conformation seems to be very stable. We were
able to inhibit rmALDH in vitro with a number of
Figure 6. Positive ion SEC-mESI-MS analysis of TPCK-inhibited
rmALDH. (A) mESI-MS analysis of TPCK-inhibited rmALDH.
Both the homotetramer (m/z ;6200–7700) and the skimmer-
induced monomer (m/z ;2200–3500) were found. (B) Trans-
formed spectrum of TPCK-inhibited rmALDH homotetramer with
a Mr of 218,646 Da, which was ;1200 Da higher than that of the
native homotetramer. (C) Transformed spectrum of TPCK-inhib-
ited rmALDH monomer with a Mr of 54,673 Da, which was ;315
Da higher than that of the native monomer. The N- or C-terminus
enzyme monomer also showed ;315 Da increase to 54,593 Da.
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inhibitors including disulfiram, prunetin, benomyl, and
TPCK, and found that inhibition of rmALDH was not
caused by disruption of the noncovalent quaternary
structure. We were able to show that these four inhib-
itors produced their effects by either covalently modi-
fying amino acid residues, or by binding to a possible
independent allosteric site which influenced substrate
and cofactor binding capacities. We have also demon-
strated that SEC-mESI-MS is a powerful tool for rapid
characterization of the influence on protein quaternary
structure upon inhibition.
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